The Cocktail Report (sound really smart around your friends):
On April 27, 2026, Veradermics announced that VDPHL01, its extended-release oral minoxidil pill, met every primary and key secondary endpoint in a Phase 2/3 clinical trial of 519 men with pattern hair loss.
Patients taking VDPHL01 once daily gained an average of 30.3 non-vellus hairs per square centimeter after six months. Twice-daily dosing produced 33.0 hairs/cm². The placebo group gained just 7.3.
Non-vellus hair refers to thick, pigmented terminal hair, the kind you actually see, as opposed to the fine, colorless "peach fuzz" that doesn't count as real regrowth.
79% of once-daily patients and 86% of twice-daily patients self-reported improvement in hair coverage. Only 36% of placebo patients said the same.
No cardiac adverse events were reported, a critical safety hurdle given that standard oral minoxidil at higher doses can cause fluid around the heart, palpitations, and blood pressure drops.
VDPHL01 uses an extended-release gel matrix that delivers minoxidil slowly and steadily, avoiding the cardiovascular spike that limits how much of the standard pill doctors can safely prescribe.
Minoxidil was originally a blood pressure medication, and dermatologists have been prescribing it off-label for hair loss without an FDA-approved oral formulation, without standardized dosing, and without robust Phase 3 safety data.
If approved, VDPHL01 would be the first new FDA-approved oral hair loss treatment in nearly 30 years, and the first ever non-hormonal oral option for both men and women.
A second Phase 3 male trial (Study 304) has completed enrollment; results expected in the second half of 2026. A female pattern hair loss trial (Study 306) is currently recruiting.
Wall Street analysts called the results a "home run," projecting $1.5 to $2 billion in U.S. annual sales if approved.
If you or someone you know has pattern hair loss, and that is roughly 80 million Americans, this trial result is the most significant development in the space in three decades.
Veradermics reported Phase 2/3 results on April 27, 2026, for VDPHL01, its oral extended-release formulation of minoxidil. Every primary and key secondary endpoint was met, hair growth was statistically significant by month two (the earliest point measured), and the safety profile was comparable to placebo.
Dermatologists already prescribe oral minoxidil off-label for hair loss, because it works better than the topical version: Rogaine absorbs at only 1 to 2% through the skin, while a pill reaches all follicles via the bloodstream. But the available pill releases minoxidil all at once, creating a cardiovascular spike that limits safe dosing to 5 mg per day.
VDPHL01 uses a gel matrix to release the drug gradually, avoiding that spike while keeping minoxidil above the hair-growth threshold for longer.
The result is a drug that outperformed the current off-label standard in efficacy while matching placebo on side effects.
Trial investigator Dr. Michael Gold put it plainly: "Dermatology has been treating hair loss with a drug borrowed from cardiology, in a formulation never intended for our patients, at doses we arrived at informally.
VDPHL01, as Gold noted, is the first oral minoxidil formulation developed specifically for hair loss rather than adapted from a blood pressure drug.
The existing alternatives each carry real drawbacks. Topical minoxidil causes scalp itchiness and flakiness for many users, while finasteride (Propecia) is linked in some patients to erectile dysfunction, anxiety, and suicidal thoughts, and is contraindicated in women of childbearing age.
VDPHL01 is non-hormonal and showed no treatment-related serious adverse events.
A second confirmatory Phase 3 male trial (Study 304) has already completed enrollment, with results due in the second half of 2026. Veradermics is also running the first-ever Phase 3 trial of an oral treatment for female pattern hair loss, a population with no FDA-approved oral options whatsoever.
An FDA submission is planned for early 2027, with approval possible by late 2027 or early 2028.
Why Should You Care?
Pattern hair loss is one of the most common age-related changes in the human body, and also one of the most emotionally significant. The existing treatments are imperfect, the options for women are especially limited, and nothing genuinely new has been approved in 30 years.
VDPHL01 is not approved yet, and two more trial readouts stand between now and a prescription. But the Phase 3 data is strong, the safety story held, and the regulatory path is clear.
Citations:
Veradermics press release. "Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial." April 27, 2026. https://www.businesswire.com/news/home/20260427832356/en/
Gardner J. "Veradermics soars on positive data for baldness treatment." BioPharma Dive. April 27, 2026. https://www.biopharmadive.com/news/veradermics-oral-minoxidil-baldness-hair-loss-study-results/818529/
Clinical Trials Arena. "Veradermics' stock grows on pivotal hair loss win." April 28, 2026. https://www.clinicaltrialsarena.com/news/veradermics-vdphl01-pattern-hair-loss-phase-ii-iii-results/
